NCT06757855View on ClinicalTrials.gov

Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 26, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2028

Conditions
CML,Blast Phase
Interventions
DRUG

Olverembatinib

"induction therapy：40mg,QOD；~consolidation maintenance therapy: If patients with CMR are reduced to 30mg."

DRUG

Venetoclax

"induction therapy：leverl 0: 100mg d-2; 200mg d-1; 400mg d1-14~leverl -1: 100mg d-2; 200mg d-1; 400mg d1-7~leverl 1: 100mg d-2; 200mg d-1; 400mg d1-21~consolidation maintenance therapy: 400mg d1-7"

DRUG

Azacitidine

"induction therapy：75mg/m2/d, d1-7~consolidation maintenance therapy: 75mg/m2/d, d1-7"

Trial Locations (1)

300020

RECRUITING

Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER